COVID-19 Information Center
- Coronavirus disease
COVID-19 Information Center
Novartis is responding to coronavirus disease (COVID-19) with safety of associates and patients globally our primary concern. We are also contributing to research efforts, supporting communities and ensuring stable supply and price of essential medicines. This information center provides a central hub for updates, guidance and other resources.
Novartis response to COVID-19
In the face of a global crisis, Novartis has quickly mobilized R&D capabilities, medicines, clinical trials expertise and philanthropic aid to address the coronavirus disease pandemic.
AveXis joins AAVCOVID vaccine program from Massachusetts Eye and Ear and Massachusetts General Hospital
Our industry is at an inflection point. Novartis research shows technology talent increasingly drawn to pharma industry since COVID-19, to solve healthcare challenges
Sandoz responds to increased demand for antibiotics and other essential medicines for patients during COVID-19
Novartis update following WHO Solidarity trial announcement
Going the extra mile to keep clinical trials on track during the COVID-19 pandemic
A Novartis team couriers an experimental treatment across Europe to a patient as transit grinds to a halt.
Novartis COVID-19 Response Fund
Novartis COVID-19 Response Fund is providing urgently-needed support for healthcare workers and communities in over 50 projects around the world.
Joining Monocle’s The Big Interview Podcast
Novartis CEO Vas Narasimhan joins Monocle’s editor in chief, Tyler Brûlé to talk about crisis management, the vaccine race and the future of work during episode 114 of The Big Interview.
Applying H1N1 learnings to COVID-19 pandemic
NYSE called Novartis CEO Vas Narasimhan to learn how Novartis is applying what they learned from fighting H1N1 to the current COVID-19 pandemic.
Streamlining systems to respond to COVID-19
Paul Aliu and his team quickly address requests for Novartis medicines during the pandemic.
